Beyond its proposed radio- and chemoresistance-conferring actions, KCa3.1’s role in cell migration and invasion is well documented17–19, and KCa3.1 targeting therapies were found to decrease glioma cell migration and invasion both in vitro and in vivo10,20,21. This evidence concerns the gene KCNN4 and central nervous system cancer.